Cushing's Syndrome Diagnostics And Therapeutics Enhancers Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 350 Million |
| Market Size (2029) | USD 686.89 Million |
| CAGR (2024 - 2029) | 9.44 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Cushing's Syndrome Diagnostics And Therapeutics Enhancers Market Analysis
The Cushing's Syndrome Diagnostics And Therapeutics Market size is estimated at USD 350 million in 2024, and is expected to reach USD 686.89 million by 2029, growing at a CAGR of 9.44% during the forecast period (2024-2029).
Cushing's syndrome (CS) is a condition that occurs when the body produces an excessive amount of the hormone cortisol over an extended period. It can be caused by medication or by a tumor. Sometimes, tumors in the pituitary gland can cause an overproduction of cortisol. The main driving factors for market growth are the increasing prevalence of Cushing's syndrome and growing research and development efforts.
CS is expected to increase the utilization of diagnostic tests and therapeutics, ultimately driving market growth during the forecast period. For instance, according to an article published in the Journal of Clinical Endocrinology and Metabolism in August 2022, CS is the most common subtype, accounting for 70%, followed by adrenal CS (ACS), 20% to 25%, and ectopic CS, 5% to 10% globally. According to the article above, the overall incidence of all-cause CS is estimated to range between 1.8 and 3.2 cases per million annually and between 0.6 and 2.6 per million per year globally. Hence, the significant prevalence of CS is expected to drive the demand for diagnostic tests and drugs, further driving the market during the forecast period.
Also, the increasing research and development activities are expected to drive the market by accelerating new product launches. For instance, according to an article published in Cancers in January 2023, drugs that target corticotroph pituitary neuroendocrine tumors have been effective for Cushing's syndrome, including cabergoline, a dopamine receptor type 2 agonist, and pasireotide, a multi-receptor-targeted somatostatin analog. Some of the drugs that target adrenal hormones have shown potential therapeutic benefits. Hence, such research activities are expected to drive the market during the forecast period.
Therefore, the rising prevalence of Cushing's syndrome and increasing research and development activities are expected to drive the studied market during the forecast period. However, the high costs of drugs are expected to restrain the market during the forecast period.
Cushing's Syndrome Diagnostics And Therapeutics Enhancers Market Trends
The Drugs Segment is Expected to Hold a Major Market Share in the Cushing's Syndrome Market
Medications are used to regulate cortisol levels when surgery and radiation are ineffective or not feasible. Medicines may also be used before surgery in people who are very sick with Cushing's syndrome. This can improve symptoms of the disease and reduce the risks of surgery. Various drugs are used in the treatment of Cushing's syndrome, such as ketoconazole, osilodrostat (Isturisa), mitotane (Lysodren), levoketoconazole (Recorlev), and metyrapone (Metopirone).
The increasing strategic activities, such as product approvals and acquisitions, are expected to drive the market during the forecast period. For instance, in January 2022, Xeris Biopharma, a biopharmaceutical company, secured approval from the US Food and Drug Administration for its steroidogenesis inhibitor, levoketoconazole. This approval specifically targets adults with Cushing’s syndrome, offering treatment when surgery is either unfeasible or has shown inefficacy. Hence, such product approvals are expected to drive the market during the forecast period.
Also, the increasing number of clinical trials is expected to drive the market during the forecast period. For instance, according to ClinicalTrials.gov updated data from June 2024, around eight drugs are in phase 3 studies for the treatment of Cushing's syndrome. Hence, the significant clinical trials in Cushing's syndrome are expected to lead to new product launches, which ultimately drive the market during the forecast period. Thus, increasing strategic activities such as product launches and rising clinical trials are expected to drive the market during the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same During the Forecast Period
The geographical analysis of the Cushing's syndrome diagnostic and therapeutics market shows that North America holds a significant market share in the global market. This is due to the rising number of Cushing's syndrome cases in the region, increasing research activities, and the presence of key players in the area.
The increasing prevalence of Cushing's syndrome is expected to drive the demand for diagnostic tests and treatment therapies for the diagnosis and treatment of Cushing's syndrome. For instance, according to an article published by the College of Dental Hygienists of Ontario in January 2022, Cushing's disease comprises about 80% of endogenous Cushing's syndrome, with population prevalence estimated at 5.5 per 100,000 population (equating to about 880 active cases in Ontario and 2,255 cases in Canada). Also, according to the American Association of Neurological Surgeons updated data from January 2022, about 10-15 people per million population are affected every year with Cushing’s syndrome in the United States, which accounts for more than 70% of cases in adults and about 60-70% of cases in children and adolescents. Hence, the significant prevalence of Cushing's syndrome is expected to drive the market during the forecast period.
Moreover, the increasing research activities in the region are expected to drive the market during the forecast period. For instance, according to ClinicalTrials.gov updated data from June 2024, around 29 clinical studies are being performed in the United States to develop new therapies for treating Cushing's syndrome. Hence, such research activities are expected to drive the market during the forecast period. Thus, the increasing prevalence of Cushing's syndrome and increasing research activities are expected to drive the market during the forecast period.
Cushing's Syndrome Diagnostics And Therapeutics Enhancers Industry Overview
The Cushing's syndrome diagnostic and treatment market is semi-consolidated due to the presence of a few major market companies operating globally and regionally. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, which help them strengthen their market position. Some of the key players in the market are Corcept Therapeutics Inc., Perrigo Co. PLC, Recordati SpA, and Xeris Biopharma Holdings Inc.
Cushing's Syndrome Diagnostics And Therapeutics Enhancers Market Leaders
-
Corcept Therapeutics Inc.
-
Perrigo Co. Plc
-
Recordati S.p.A
-
Xeris Biopharma Holdings Inc.
-
Crinetics Pharmaceuticals, Inc.
*Disclaimer: Major Players sorted in no particular order
Cushing's Syndrome Diagnostics And Therapeutics Enhancers Market News
- April 2024: Ubie and Cushing's Support and Research Foundation (CSRF) entered a partnership to shorten the time to diagnose patients with Cushing's disease (CD) and Cushing's syndrome (CS).
- April 2024: Corcept Therapeutics reported the positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all endogenous Cushing’s syndrome etiologies.
Cushing's Syndrome Diagnostics And Therapeutics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and market definitions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Cushing's Syndrome
4.2.2 Increasing Research and Development Activities
4.3 Market Restraints
4.3.1 High Cost of Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Treatment Type
5.1.1 Surgery
5.1.2 Radiation Therapy
5.1.3 Drugs
5.2 By Diagnostic Tests
5.2.1 Petrosal Sinus Sampling
5.2.2 Saliva Test
5.2.3 Urine and Blood Tests
5.2.4 Imaging Tests
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Corcept Therapeutics Inc.
6.1.2 Perrigo Co. PLC
6.1.3 Recordati SpA
6.1.4 Xeris Biopharma Holdings Inc.
6.1.5 Crinetics Pharmaceuticals Inc.
6.1.6 Cyclacel Pharmaceuticals
6.1.7 Sparrow Pharmaceuticals
6.1.8 Stero Therapeutics
6.1.9 OMass Therapeutics
6.1.10 Cipla Inc.
6.1.11 Hikma Pharmaceuticals PLC
- *List Not Exhaustive
Cushing's Syndrome Diagnostics And Therapeutics Enhancers Industry Segmentation
As per the scope of the report, Cushing's syndrome occurs when the body produces an excessive amount of the hormone cortisol over a prolonged period. Some of the symptoms that arise in CS patients are a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin.
The Cushing's syndrome diagnostics and therapeutics market is segmented into treatment type, diagnosis, distribution channel, and geography. By treatment type, the market is segmented into surgery, radiation therapy, and drugs. By diagnostic tests, the market is segmented into petrosal sinus sampling, saliva tests, urine and blood tests, and imaging tests. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across significant global regions. The report offers the value (USD) for the above segments.
| By Treatment Type | |
| Surgery | |
| Radiation Therapy | |
| Drugs |
| By Diagnostic Tests | |
| Petrosal Sinus Sampling | |
| Saliva Test | |
| Urine and Blood Tests | |
| Imaging Tests |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Online Pharmacies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Cushing's Syndrome Diagnostics And Therapeutics Market Research Faqs
How big is the Cushing's Syndrome Diagnostics And Therapeutics Market?
The Cushing's Syndrome Diagnostics And Therapeutics Market size is expected to reach USD 350 million in 2024 and grow at a CAGR of 9.44% to reach USD 686.89 million by 2029.
What is the current Cushing's Syndrome Diagnostics And Therapeutics Market size?
In 2024, the Cushing's Syndrome Diagnostics And Therapeutics Market size is expected to reach USD 350 million.
Who are the key players in Cushing's Syndrome Diagnostics And Therapeutics Market?
Corcept Therapeutics Inc., Perrigo Co. Plc, Recordati S.p.A, Xeris Biopharma Holdings Inc. and Crinetics Pharmaceuticals, Inc. are the major companies operating in the Cushing's Syndrome Diagnostics And Therapeutics Market.
Which is the fastest growing region in Cushing's Syndrome Diagnostics And Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Cushing's Syndrome Diagnostics And Therapeutics Market?
In 2024, the North America accounts for the largest market share in Cushing's Syndrome Diagnostics And Therapeutics Market.
What years does this Cushing's Syndrome Diagnostics And Therapeutics Market cover, and what was the market size in 2023?
In 2023, the Cushing's Syndrome Diagnostics And Therapeutics Market size was estimated at USD 316.96 million. The report covers the Cushing's Syndrome Diagnostics And Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Cushing's Syndrome Diagnostics And Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Cushing's Syndrome Diagnostics And Therapeutics Industry Report
Statistics for the 2024 Cushing's Syndrome Diagnostics And Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Cushing's Syndrome Diagnostics And Therapeutics analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
